The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Improving diversity in phase I oncology clinical trials: A single institution experience at the University of Colorado Cancer Center.
 
Ahmed Alsafar
No Relationships to Disclose
 
Sama Kareem
No Relationships to Disclose
 
Bradley Corr
Consulting or Advisory Role - AstraZeneca/Merck (Inst); Corcept Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunogen; Imvax; Merck (Inst); Zentalis (Inst)
Research Funding - Clovis Oncology (Inst); Immunogen (Inst)
 
Christopher Hanyoung Lieu
Consulting or Advisory Role - Amgen (Inst)
Research Funding - Genentech (Inst)
 
Breelyn A. Wilky
Consulting or Advisory Role - AADi; Adcendo; Boehringer Ingelheim; Deciphera; Epizyme; Polaris; SpringWorks Therapeutics
Research Funding - Exelixis
Travel, Accommodations, Expenses - Agenus
 
S. Lindsey Davis
Stock and Other Ownership Interests - Johnson & Johnson/MedTech
Speakers' Bureau - Allergan (I)
Research Funding - Boston Scientific (I); Bristol-Myers Squibb (Inst); EMD Serono (Inst); I-Mab (Inst); Merck (Inst); ORIC Pharmaceuticals (Inst); Symphogen (Inst); TriSalus Life Sciences (Inst); Tvardi Therapeutics (Inst)
 
David Ross Camidge
Honoraria - Abbvie; Amgen Astellas BioPharma; Anheart Therapeutics; Apollomics; AstraZeneca; BeiGene; BeiGene; bio-thera; Daiichi Sankyo; Dizal Pharma; Elevation Oncology; EMD Serono; Helsinn Therapeutics; Hengrui Pharmaceutical; Hummingbird; Janssen; Kestrel Labs; Lilly; Mersana; Mirati Therapeutics; nalo therapeutics; Nuvalent, Inc.; OnKure; Puma Biotechnology; Ribon Therapeutics; Roche; Sanofi; Seagen; takeda; Turning Point Therapeutics
Research Funding - Inivata (Inst)
 
Antonio Jimeno
Stock and Other Ownership Interests - Champions Oncology; Suvica
Consulting or Advisory Role - BlueDot; Purple Biotech
Research Funding - AstraZeneca (Inst); Bayer (Inst); Cantargia AB (Inst); Celldex (Inst); Debiopharm Group (Inst); Flamingo Pharma (Inst); Genocea Biosciences (Inst); HolyStone Therapeutics (Inst); Iovance Biotherapeutics (Inst); KHAR Medical (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); SQZ Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Suvica
 
Andrew Nicklawsky
No Relationships to Disclose
 
Jessica Dreger McDermott
No Relationships to Disclose
 
Jennifer Robinson Diamond
Leadership - OnKure (Inst)
Stock and Other Ownership Interests - OnKure
Consulting or Advisory Role - Gilead Sciences (Inst)
Research Funding - Adlai Nortye (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cosmo Pharmaceuticals (Inst); Deciphera (Inst); Gilead Sciences (Inst); Merck (Inst); OnKure (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - OnKure